CTSL and invasive carcinoma: In the constitutive model of PNET progression—RT2—the proliferation rate in advanced stages of tumor progression (insulinomas and invasive carcinomas) in the cathepsin L-deficient background was significantly reduced by ~90% when compared to control tumors with WT CTS L [12].